期刊文献+

银杏内酯PELGE纳米粒的制备及理化性质 被引量:5

Preparation and Physicochemical Properties of Ginkgolide PELGE Nanoparticles
下载PDF
导出
摘要 采用共沉淀法制备银杏内酯PELGE纳米粒,正交试验设计优化处方,并考察了优化制品的外观和体外释放行为。结果表明,所得纳米粒外观圆整,包封率为(66.9±1.7)%,粒径为(123.3±44.0)nm,体外24h累积释放率为60.2%。 The orthogonal design was used to optimize the formulation of ginkgolide nanoparticles by coprecipitation method using poly [monomethoxy ethylene glycol-b-(DL-lactic acid-co-glycolic acid)-b-monomethoxy ethylene glycol] (PELGE) as material. The appearance and in vitro release of the optimized products were investigated. The results showed that the products were spherical with the mean diameter of (123.3±44.0)nm and the mean entrapment efficiency of (66.9±1.7) %. The 24h accumulative release was 60.2 %.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2007年第6期431-434,共4页 Chinese Journal of Pharmaceuticals
关键词 银杏内酯 纳米粒 制备工艺 理化性质 ginkgolide nanoparticle preparation physicochemical property
  • 相关文献

参考文献10

  • 1马丹丹,孙立红.银杏萜内酯的研究进展[J].河北职工医学院学报,2002,19(1):46-47. 被引量:11
  • 2陈维军,谢笔钧,胡慰望.银杏萜内酯的化学结构及药理作用研究进展[J].中国药学杂志,1998,33(9):516-519. 被引量:58
  • 3段友容,张志荣,唐永刚,林芸竹.mPEG-PLGA-mPEG纳米粒的体外降解规律的研究[J].生物医学工程学杂志,2004,21(6):921-925. 被引量:11
  • 4Panagi Z,Beletsi A,Evangelatos G,et al.Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles[J].Int J Pharm,2001,221(1-2):143-152.
  • 5Mauri P,Simonetti P,Gardana C,et al.Liquid chromatography/atmospheric pressure chemical ionization mass spectrometry of terpene lactones in plasma of volunteers dosed with Ginkgo biloba L.extracts[J].Rapid Commun Mass Spectrom,2001,15(12):929-934.
  • 6Biber A,Koch E.Bioavailability of ginkgolides and bilobalide from extracts of Ginkgo biloba using GC/MS[J].Planta Med,1999,65(2):192-193.
  • 7Redhead HM,Davis SS,Illum L.Drug delivery in poly (lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908:in vitro characterisation and in vivo evaluation[J].J Controlled Release,2001,70(3):353-363.
  • 8陈蜀,张志荣,石海涛,卢颖名.复乳法制备阿柔比星A的聚乳酸聚乙醇酸共聚物纳米粒影响包封率因素考察[J].中国抗生素杂志,2005,30(6):338-340. 被引量:8
  • 9Hodoshima N,Udagaw C,Ando H,et al.Lipid nanoparticles for delivering antitumor drugs[J].Int J Pharm,1997,146(1):81-92.
  • 10Govender T,Stolnik S,Garnett MC,el al.PLGA nanoparticles prepared by nanoprecipitation:drug loading and release studies of a water soluble drug[J].J Controlled Release,1999,57(2):171-185.

二级参考文献31

  • 1蒋学华,廖工铁.阿克拉霉素A在聚氰基丙烯酸异丁酯毫微粒上的吸附规律研究[J].华西医科大学学报,1995,26(2):163-166. 被引量:4
  • 2王兴鹏,袁耀宗,徐家裕.银杏苦内酯对急性胰腺炎大鼠的治疗作用及机制[J].中国药理学通报,1995,11(3):199-201. 被引量:22
  • 3陈仲良.银杏提取物的化学成分和制剂的质量[J].中国药学杂志,1996,31(6):326-331. 被引量:102
  • 4[1]Maruyama M,Terahara A,Nakanishi K.The inkgolides I.Isolation and characterization of the various groups[J].Tetrahedron Lett,1967,(4):299.
  • 5[4]Braquet P.The effects of PAF-acether on the cardiovascular system and their inhibition by a new highly specific PAF-acether receptor antagonist BN52021[J].Pharmacol Res Communi,1986,18(8):717.
  • 6[5]Krieglstein J.Neuroprotective effective of Ginkgo Biloba constituents[J].Eur J Pharmacol Sci,1995,3(1):39.
  • 7[6]Lee W,Rhim B,Hong K.A study on cerebral ischemiare perfusion injury involvement of PAF[J].Kor Pharmacol,1993,29(1):1.
  • 8[7]Choopra K,Singh M,Gupta S.Involvement of oxygen free radicals in the action of BN52021 to limit myocardial infarct size[J].Methods Find Exp Clin Pharmacol,1993,15(7):437.
  • 9[8]Koltai M,Hosford D,Guinot P,et al.PAF:A review of its effects,antagonists and possible future clinical implications(part2)[J].Eur J Pharmacol,1989,164(2):293.
  • 10[9]Borobia F,Figureras J,Escriba J,et al.Platelet activating factor antagonist BN52021 improves survival in normothermic liver ischemia in rats[J].Transplant Proc,1993,25(4):2543.

共引文献83

同被引文献114

引证文献5

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部